On the public citation graph

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients

https://doi.org/10.1183/09059180.00001912
0 signed · 16 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s12185-011-0997-2openalex-snapshot
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide
inferredcites →https://doi.org/10.1056/nejmoa070596openalex-snapshot
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
inferredcites →https://doi.org/10.1159/000305213openalex-snapshot
A Case of Lenalidomide-Induced Hypersensitivity Pneumonitis
inferredcites →https://doi.org/10.1177/1078155211408374openalex-snapshot
Reversible pulmonary toxicity due to lenalidomide
inferredcites →https://doi.org/10.1378/chest.06-1734openalex-snapshot
Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide
inferredcites →https://doi.org/10.1378/chest.10-2082openalex-snapshot
Acute Lung Toxicity Related to Pomalidomide
inferredcites →https://doi.org/10.1592/phco.30.3.325openalex-snapshot
Lenalidomide‐Induced Interstitial Lung Disease

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4608621openalex-extracted
Synergism and Antagonism of Lenalidomide-(Β-D-Ribofuranose 2',3'-Phosphodiester)-Paclitaxel as an Anticancer Codrug for Selective Delivery
inferred← citeshttps://doi.org/10.1002/rcr2.233openalex-snapshot
Lenalidomide‐induced eosinophilic pneumonia
inferred← citeshttps://doi.org/10.1007/s11899-015-0274-1openalex-snapshot
A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies
inferred← citeshttps://doi.org/10.1007/s40278-013-2713-xopenalex-snapshot
Lenalidomide
inferred← citeshttps://doi.org/10.1021/acs.orglett.4c03662openalex-snapshot
β- d -Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development
inferred← citeshttps://doi.org/10.1039/d5nj00425jopenalex-snapshot
Designing lenalidomide cocrystals with an extended-release profile for improved pulmonary drug delivery
inferred← citeshttps://doi.org/10.1177/10781552221124533openalex-snapshot
Lenalidomide induced pneumonitis
inferred← citeshttps://doi.org/10.1186/s12890-026-04438-1openalex-snapshot
Pomalidomide-induced acute eosinophilic pneumonia: a case report
inferred← citeshttps://doi.org/10.7759/cureus.91885openalex-snapshot
Persistent Respiratory Symptoms Post-COVID-19 in a Non-Hodgkin Lymphoma Patient: A Case Report
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.